Trial Profile
A phase II study of gemcitabine in transitional cell carcinoma of the urothelium
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Jan 2007 The expected completion date for this trial is now 1 Sep 2006.
- 16 Oct 2006 Status change
- 26 Nov 2005 New trial record.